1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 6,350 | 6,500 | 21:01 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.09. | Biocytogen and Qilu Pharmaceutical sign agreement for VHH antibody molecule | 3 | Pharmaceutical Technology | ||
| BIOCYTOGEN PHARMACEUTICALS Aktie jetzt für 0€ handeln | |||||
| 02.09. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience | 382 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd.... ► Artikel lesen | |
| 27.08. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Reports Climb In H1 Bottom Line | 1 | RTTNews | ||
| 27.08. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2026 THIRD EXTRAORDINARY GENERAL MEETING HELD ON WEDNESDAY, SEPTEMBER 16, 2026 | - | HKEx | ||
| 27.08. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | - | HKEx | ||
| 27.08. | BIOCYTOGEN-B (02315): CHANGE IN IMPLEMENTATION METHOD OF CERTAIN PROCEEDS-FUNDED PROJECT; AND NOTICE OF THE 2026 THIRD EXTRAORDINARY GENERAL MEETING | 1 | HKEx | ||
| 27.08. | BIOCYTOGEN-B (02315): INTERIM RESULTS ANNOUNCEMENT FOR THE SIX MONTHS ENDED JUNE 30, 2026 | 1 | HKEx | ||
| 17.08. | BIOCYTOGEN-B (02315): DATE OF BOARD MEETING | - | HKEx | ||
| 06.08. | BIOCYTOGEN-B (02315): INSIDE INFORMATION ANNOUNCEMENT OF ESTIMATED INTERIM RESULTS FOR 2026 | 1 | HKEx | ||
| 08.07. | Biocytogen and Whitehawk partner to develop ADCs | 1 | Pharmaceutical Technology | ||
| 07.07. | Biocytogen und Whitehawk Therapeutics vereinbaren weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten (ADC) | 447 | Business Wire | Biocytogen (SSE: 688796; HKEX: 02315) und Whitehawk Therapeutics, Inc. ("Whitehawk", Nasdaq: WHWK) gaben heute eine weltweite Zusammenarbeit zur Entwicklung von bispezifischen Antikörper-Wirkstoff-Konjugaten... ► Artikel lesen | |
| 07.07. | Whitehawk swoops in for five ADCs via development deal with China's Biocytogen | 3 | FierceBiotech | ||
| 07.07. | Biocytogen and Whitehawk Therapeutics Enter Global Collaboration for Bispecific Antibody ADC Development | 485 | Business Wire | Biocytogen (SSE: 688796; HKEX: 02315) and Whitehawk Therapeutics, Inc. ("Whitehawk," Nasdaq: WHWK) today announced a global collaboration to develop bispecific antibody-drug conjugates (BsADC). Biocytogen... ► Artikel lesen | |
| 29.06. | Biocytogen Pharmaceuticals (Beijing) Co., Ltd.: Gericht gibt Biocytogen im wegweisenden Patentstreit gegen Harbour in Bezug auf RenNano Recht | 456 | Business Wire | Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen", SSE: 688796; HKEX: 02315) hat heute bekannt gegeben, dass das Gericht für geistiges Eigentum in Shanghai ein erstinstanzliches Zivilurteil... ► Artikel lesen | |
| 29.06. | BIOCYTOGEN-B (02315): VOLUNTARY ANNOUNCEMENT DEVELOPMENT OF LITIGATION | 2 | HKEx | ||
| 25.06. | BIOCYTOGEN-B (02315): POLL RESULTS OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON JUNE 25, 2026 | 1 | HKEx | ||
| 16.06. | Biocytogen erhält die vollumfängliche AAALAC-Akkreditierung, was die Exzellenz in der translationalen Forschung und der Wirkstoffentdeckung unterstreicht | 359 | Business Wire | Biocytogen teilte heute mit, dass seine Forschungseinrichtung in Boston die Vollakkreditierung durch AAALAC International erhalten hat, eine weltweit renommierte Organisation, deren Ziel die Förderung... ► Artikel lesen | |
| 15.06. | Biocytogen Earns Full AAALAC Accreditation, Reinforcing Excellence in Translational Research and Drug Discovery | 300 | Business Wire | Biocytogen today announced that its Boston research facility has been awarded Full Accreditation by AAALAC International, a globally recognized organization dedicated to promoting excellence in laboratory... ► Artikel lesen | |
| 04.06. | BIOCYTOGEN-B (02315): FORM OF PROXY FOR THE USE AT THE 2026 SECOND EXTRAORDINARY GENERAL MEETING HELD ON THURSDAY, JUNE 25, 2026 | - | HKEx | ||
| 04.06. | BIOCYTOGEN-B (02315): NOTICE OF THE 2026 SECOND EXTRAORDINARY GENERAL MEETING | 1 | HKEx |
1 2 3 Weiter >>
54 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| MEDIGENE | 0,005 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 30.06.2026 | The following instruments on Boerse Frankfurt do have their last trading day on 30.06.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 30.06.2026ISIN NameBE0003593044 COFINIMMOCA8765111064 TASEKO... ► Artikel lesen | |
| BIOFRONTERA | 2,400 | +1,69 % | PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale | DJ PTA-Adhoc: Biofrontera AG: Biofrontera AG beschließt Vorbereitung des Wechsels vom regulierten Markt (Prime Standard) in das Börsensegment Scale
Veröffentlichung von Insiderinformationen gemäß... ► Artikel lesen | |
| CLINUVEL | 5,060 | -0,08 % | Dividendenbekanntmachungen (03.09.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) ADMIRAL GROUP PLC GB00B02J6398 0,705 GBP 0,8204 EUR AEGON LTD ADR US0076CA1045 0,2455 USD 0,2118 EUR AMCOR PLC CDIS AU000000AMC4 0... ► Artikel lesen | |
| EDITAS MEDICINE | 2,450 | +2,51 % | Editas Medicine, Inc.: Editas Medicine Appoints Dan Ory, M.D., as Chief Medical Officer | Experienced biotechnology executive with more than 25 years of leadership in cardiovascular and genetic medicine to lead clinical development Appointment strengthens executive leadership team as... ► Artikel lesen | |
| ASEP MEDICAL | 0,085 | +6,25 % | ASEP Medical Holdings Inc (2): ASEP to reduce ABT, Sepset shareholdings to 45% | ||
| CELLECTAR BIOSCIENCES | 2,350 | -0,63 % | Cellectar Biosciences, Inc.: Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates | Site Activation Initiated for Confirmatory Phase 3 Study of Iopofosine I 131 with New Drug Application Submission Planned for mid-2027 under the FDA's Accelerated Approval Program Presented Data from... ► Artikel lesen | |
| CARDIFF ONCOLOGY | 0,906 | +0,83 % | Cardiff Oncology, Inc.: Cardiff Oncology Reports Second Quarter 2026 Results and Provides Business Update | Positive Phase 2 CRDF-004 data presented in an oral session at ASCO support advancement of 30 mg onvansertib plus FOLFIRI/bevacizumab into planned registrational program for first-line RAS-mutated... ► Artikel lesen | |
| CLEAN HARBORS | 269,60 | -0,74 % | William Blair initiates Clean Harbors stock with Outperform rating | ||
| MESOBLAST | 1,286 | -2,72 % | Novo Nordisk machte GLP-1 zum Milliardenmarkt, CAR-T die Krebsmedizin - welche Biotech-Plattform kommt als Nächstes? | ||
| SPERO THERAPEUTICS | 1,008 | -0,20 % | Spero Therapeutics, Inc.: Spero Therapeutics Announces Second Quarter 2026 Operating Results and Provides Business Update | Entered an exclusive license agreement with Innovent Biologics for SP001, a Phase 2-ready, third-generation anti-CD40L antibody for immune-mediated diseases U.S. Food and Drug Administration approved... ► Artikel lesen | |
| LIR LIFE SCIENCES | 0,172 | 0,00 % | Lir Life Sciences Corp.: LIR Life Sciences Signs Development Services Agreement with Oxygen Handel GmbH to Advance Regulatory and Preclinical Roadmap for Transdermal Obesity Pipeline | VANCOUVER, WA / ACCESS Newswire / July 16, 2026 / LIR Life Sciences Corp. (CSE:SKNY)(OTCPK:BBCMF)(Frankfurt:N790, WKN: A41QA9) ("LIR" or the "Company") is pleased to announce that it has entered into... ► Artikel lesen | |
| PROTALIX BIOTHERAPEUTICS | 2,230 | -3,04 % | Protalix BioTherapeutics, Inc.: Protalix BioTherapeutics Reports Second Quarter 2026 Financial and Business Results | Company to host conference call and webcast today at 8:00 a.m. EDT
Revenues from selling goods increased to $19.8 million in the second quarter of 2026, up $4.4... ► Artikel lesen | |
| CSTONE PHARMACEUTICALS | 0,661 | -1,40 % | CSTONE PHARMA-B (02616): VOLUNTARY ANNOUNCEMENT - THE COMPANY INCLUDED IN SOUTHBOUND STOCK CONNECT | ||
| PALVELLA THERAPEUTICS | 135,00 | +3,05 % | Palvella Therapeutics Inc.: Palvella Therapeutics Appoints James R. Treat, M.D., Nationally Recognized Pediatric Dermatologist as Chief Medical Officer | Brings expertise in cutaneous vascular anomalies, including microcystic lymphatic malformations, venous malformations and angiokeratomas Leader in pediatric dermatology with nearly 20 years of distinguished... ► Artikel lesen | |
| PURPLE BIOTECH | 1,730 | -5,98 % | PURPLE BIOTECH LTD. - 6-K, Report of foreign issuer |
Das Unternehmen BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,300 (-4,51 %) liegt der Kurs bei 6,350 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOCYTOGEN PHARMACEUTICALS BEIJING CO LTD finden Sie auf Wallstreet Online.